Buy Sermorelin

Sermorelin (also known as GRF 1-29) is available directly from New-U Research Compounds at https://new-u.io/peptide/sermorelin. Every batch is independently third-party tested by Janoshik Analytics and Freedom Diagnostics to >99% HPLC purity, supplied as lyophilised research-grade material, and shipped direct from source worldwide (approximately 6–14 business days).

Sermorelin starts at $110 for a 10-vial research pack (5mg per vial) at New-U Research Compounds, with 2 pack sizes available. Orders over $300 ship free.

Yes. Every Sermorelin batch is verified by independent laboratories (Janoshik Analytics and Freedom Diagnostics) for identity and purity, with a batch-linked Certificate of Analysis confirming >99% purity by HPLC area normalisation.

Sermorelin ships direct from source, discreetly worldwide with cold-chain handling where required. Delivery is approximately 6–14 business days worldwide. Shipping is free on orders over $300. Card and cryptocurrency payments are accepted.

In the United States, Sermorelin is sold strictly for laboratory and research purposes only. It is not approved by the FDA for human consumption and is not sold for that purpose. Regulatory status varies by jurisdiction — buyers are responsible for compliance in their own region.

Sermorelin (GHRH 1-29), truncated growth hormone-releasing hormone fragment retaining full GHRHR agonist activity for pulsatile GH research. New-U supplies Sermorelin as research-grade reference material for laboratory and in-vitro or animal-model investigation only. Mechanism, pharmacokinetics and study context are summarised on the Sermorelin research profile. Not for human use.

Reconstitution volumes and dosing reported in the literature for Sermorelin are described in research-model terms only. New-U Research Compounds supplies Sermorelin strictly for laboratory research and does not provide human-use dosing guidance. Reconstitution math and study-reported ranges are covered on the full research profile.

Yes. Sermorelin can be ordered online directly from New-U Research Compounds with card or cryptocurrency, shipped direct from source discreetly worldwide. Delivery is approximately 6–14 business days worldwide. Free shipping applies to orders over $300.

Sermorelin ships in 10-vial research packs as standard, in 2 pack sizes — the larger mg vials lower the per-mg cost. Multi-pack orders get direct-from-source pricing and free shipping over $300. For wholesale or recurring laboratory-supply volumes, contact New-U Research Compounds at https://new-u.io/contact.

For research-grade Sermorelin, verify four things: (1) independent third-party purity testing with a batch-linked Certificate of Analysis — New-U uses Janoshik Analytics and Freedom Diagnostics at >99% HPLC; (2) lyophilised material with documented storage and handling; (3) transparent direct-from-source pricing rather than marketplace markup; and (4) clear research-use-only framing. New-U Research Compounds meets all four at https://new-u.io/peptide/sermorelin.

HGH is the finished hormone and directly activates the GH receptor on every tissue. Sermorelin works one step upstream - it tells the pituitary to secrete its own GH in a physiologic pulse, preserving somatostatin feedback. That generally produces a more natural release pattern but a lower peak than direct HGH dosing.

The body naturally releases most of its GH during early deep sleep via a hypothalamic GHRH pulse. Evening dosing of sermorelin aligns the induced pulse with this natural rhythm, amplifying the physiologic nocturnal surge rather than creating a new one at an unusual time.

Yes - combining a GHRH analog with a ghrelin-receptor agonist is a common research pairing. The two mechanisms are complementary (GHRHR plus GHSR), and the combined GH release is larger than either peptide alone in published studies.

Keep the lyophilised powder frozen at −20 °C. After reconstitution with bacteriostatic water, refrigerate at 1-6 °C and protect from light. Sermorelin is relatively stable once reconstituted but should be used within the standard peptide-stability window.

Sermorelin is a synthetic 29-amino-acid fragment of growth-hormone-releasing hormone (GHRH 1-29). In research models it binds the GHRH receptor on the anterior pituitary and prompts the gland to synthesise and release the body's own growth hormone in a natural pulse, rather than supplying growth hormone directly. New-U supplies sermorelin strictly for laboratory research use only.

In the clinical and preclinical literature, sermorelin-induced GH release has been studied for downstream effects on the GH/IGF-1 axis - body composition, sleep architecture, recovery markers and IGF-1 elevation - while preserving the pituitary's own somatostatin feedback. These are research findings; sermorelin is not sold for human use and New-U makes no therapeutic claims.

Published research and the historical clinical record (sermorelin was once marketed as Geref) describe microgram-to-low-milligram subcutaneous amounts once daily, typically at night to match the natural nocturnal GH pulse. New-U publishes this only as descriptive research context - it is not a dosing instruction, and sermorelin is supplied strictly for laboratory research, not human use.

The research and historical clinical literature most commonly note injection-site reactions (redness, swelling), occasional flushing, headache or transient dizziness; serious effects are uncommon at the amounts studied because the pituitary's own feedback caps GH output. This is summarised research context, not medical advice - sermorelin is a research compound, not an approved medicine.

Sermorelin is a GHRH analogue (it acts on the GHRH receptor); ipamorelin is a selective ghrelin-receptor (GHSR) agonist. They drive growth-hormone release through two different receptors, which is why they are frequently co-studied as a complementary pair. See our Ipamorelin vs Sermorelin research comparison for the full mechanism-by-mechanism breakdown.

IGF-1 and GH-pulse changes are measurable within days to weeks in study settings, while body-composition and sleep endpoints are typically assessed over 8-24 weeks of continued research dosing. Timelines depend entirely on the protocol and endpoint measured. Reported for research context only - not a human-use claim.